Exelixis (EXEL) Short-term Investments (2010 - 2026)
Exelixis (EXEL) recorded quarterly Short-term Investments of $551.1 million in Q2 2026, down 4.43% quarter-over-quarter from $576.6 million in Q1 2026, and down 34.98% on a YoY basis from $847.6 million in Q2 2025.
Exelixis (EXEL) Short-term Investments (2010 - 2026) Analysis & Trends
Exelixis' Short-term Investments history runs 17 years deep, the most recent figure standing at $551.1 million for Q2 2026.
- In Q2 2026, Short-term Investments fell 34.98% year-over-year to $551.1 million; the TTM figure through Apr 2026 stood at $551.1 million (down 34.98% YoY), while the FY2026 annual figure was $576.6 million, down 35.5% from the prior year.
- Short-term Investments was $551.1 million for Q2 2026 at Exelixis, down from $576.6 million in the prior quarter.
- In the past five years, Short-term Investments ranged from a high of $930.8 million in Q3 2024 to a low of $551.1 million in Q2 2026.
- Historically, Short-term Investments has averaged $764.3 million across 5 years, with a median of $802.3 million in 2023.
- The sharpest annual moves came in 2024 and 2026: Short-term Investments surged 31.74% in 2024, then slumped 35.5% in 2026.
- A 5-year view of Short-term Investments shows it stood at $807.3 million in 2022, then slipped by 9.29% to $732.3 million in 2023, then increased by 27.11% to $930.8 million in 2024, then sank by 34.23% to $612.2 million in 2025, then decreased by 9.99% to $551.1 million in 2026.
- The last three Short-term Investments figures came in at $551.1 million (Q2 2026), $576.6 million (Q1 2026), and $612.2 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Exelixis | 13.37 Bn | 12.59 Bn | 590.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 551.06 Mn |
| Jan 2, 2026 | 576.60 Mn |
| Oct 3, 2025 | 612.24 Mn |
| Jul 4, 2025 | 626.67 Mn |
| Apr 4, 2025 | 847.56 Mn |
| Jan 3, 2025 | 893.90 Mn |
| Sep 27, 2024 | 930.82 Mn |
| Jun 28, 2024 | 803.54 Mn |
| Mar 29, 2024 | 703.70 Mn |
| Dec 29, 2023 | 732.31 Mn |
| Sep 29, 2023 | 706.53 Mn |
| Jun 30, 2023 | 802.34 Mn |
| Mar 31, 2023 | 772.54 Mn |
| Dec 30, 2022 | 807.27 Mn |
| Sep 30, 2022 | 871.71 Mn |
| Jul 1, 2022 | 907.94 Mn |
| Apr 1, 2022 | 847.06 Mn |
| Dec 31, 2021 | 819.91 Mn |
| Oct 1, 2021 | 835.41 Mn |
| Jul 2, 2021 | 854.17 Mn |